Delta-19

About Vivaldi Biosciences

Vivaldi Biosciences leverages its proprietary Delta NS1 platform to create intranasal, broadly protective vaccines. The platform's key innovation is the deletion of the NS1 gene, which disables viral replication and, uniquely, induces a potent local interferon response for enhanced mucosal and systemic immunity. With its lead universal flu vaccine, DeltaFLU, in Phase 2 and a combination COVID-19/flu candidate in preclinical development, Vivaldi aims to address significant unmet needs in respiratory disease prevention through a needle-free, potentially more effective vaccination strategy.

Therapeutic Areas